藥明康德(603259.SH):藥明基金一期擬認購D3 Bio2100萬股A-1批次優先股
格隆匯11月17日丨藥明康德(603259.SH)公佈,公司全資子企業WuXi Pharma TechHealthcare Fund I L.P.(以下簡稱“藥明基金一期”)擬認購D3 Bio, Inc.(以下簡稱“D3 Bio”)新發行的2100萬股A-1批次優先股股份,認購價格為1美元/股,金額合計2100萬美元,交易完成後持有D3 Bio的股權比例約為16.67%(全面攤薄和轉換基礎上)。
D3 Bio是一家初創的生物製藥企業,目前尚無任何藥物可用於商業化銷售。D3 Bio的大多數在研產品均處於臨牀前階段,其業務未來能否成功取決於這些在研產品的研發結果。作為一家初創生物製藥企業,D3 Bio的業務失敗風險較高,如果其研發業務失敗,公司可能無法收回投資。
D3 Bio目前尚未取得任何收入,且其未來能否產生收入取決於其在研產品是否能夠完成臨牀試驗、獲得監管批准併成功商業化等因素。若D3 Bio所研發的產品未能成功商業化,其可能無法創收並盈利。
D3 Bio進行藥品研發需要大量長期的資本投入,且其能否成功取決於未來的臨牀試驗和監管審批結果以及其他競爭性產品的研發和上市進程,因此對於D3 Bio的投資具有較高不確定性。如果D3 Bio本輪融資因先決條件未能滿足而無法完成或其後續無法獲得進一步融資,可能會對其業務產生重大不利影響,並導致公司的投資失敗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.